Here are the 424B prospectus supplements from XORTX Therapeutics Inc. (XRTX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow XRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XRTX filings page.
XORTX Therapeutics is offering 183,577 common shares and Pre-Funded Warrants to purchase up to 2,475,997 common shares pursuant to this prospectus. The offering was conducted on a reasonable best efforts basis and terminated on May 13, 2026 upon entry into a placement agent agreement.
The company priced Shares at $1.88 per Share and Pre-Funded Warrants at $1.8799. Net proceeds are expected to be approximately $4.7 million (after fees), intended for R&D, working capital and investor relations including up to $2 million to IR Agency LLC. The offering assumes shareholder and exchange actions already completed, including a 5:1 share consolidation and the April 13, 2026 Vectus asset acquisition.